HK1226390A1 - 縮合5-噁唑烷酮衍生物 - Google Patents

縮合5-噁唑烷酮衍生物

Info

Publication number
HK1226390A1
HK1226390A1 HK16114601A HK16114601A HK1226390A1 HK 1226390 A1 HK1226390 A1 HK 1226390A1 HK 16114601 A HK16114601 A HK 16114601A HK 16114601 A HK16114601 A HK 16114601A HK 1226390 A1 HK1226390 A1 HK 1226390A1
Authority
HK
Hong Kong
Prior art keywords
condensed
oxazolidinone derivative
oxazolidinone
derivative
Prior art date
Application number
HK16114601A
Other languages
English (en)
Inventor
Yohei Ikuma
Masato Iwata
Chongwang Lee
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of HK1226390A1 publication Critical patent/HK1226390A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16114601A 2014-01-14 2016-12-22 縮合5-噁唑烷酮衍生物 HK1226390A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014004252 2014-01-14

Publications (1)

Publication Number Publication Date
HK1226390A1 true HK1226390A1 (zh) 2017-09-29

Family

ID=53542636

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16114601A HK1226390A1 (zh) 2014-01-14 2016-12-22 縮合5-噁唑烷酮衍生物

Country Status (9)

Country Link
US (1) US9718840B2 (zh)
EP (1) EP3095786A4 (zh)
JP (1) JPWO2015107724A1 (zh)
KR (1) KR20160107322A (zh)
CN (1) CN106103453A (zh)
AU (1) AU2014378428A1 (zh)
CA (1) CA2939326A1 (zh)
HK (1) HK1226390A1 (zh)
WO (1) WO2015107724A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
NO2760821T3 (zh) 2014-01-31 2018-03-10
IL298983B2 (en) 2014-01-31 2024-03-01 Bristol Myers Squibb Co Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR20180058815A (ko) * 2015-10-01 2018-06-01 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
US10344039B2 (en) 2015-10-29 2019-07-09 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use
CN107200726B (zh) * 2016-03-17 2021-04-06 江苏恒瑞医药股份有限公司 吡咯烷-酰胺类衍生物、其制备方法及其在医药上的应用
TW201808908A (zh) 2016-08-22 2018-03-16 美商默沙東藥廠 因子XIa抑制劑
CN107115334A (zh) * 2017-03-04 2017-09-01 王宏 一种治疗免疫性流产的药物组合物
EP3600451A4 (en) * 2017-03-29 2021-04-14 Minerva Biotechnologies Corporation AGENTS TO DIFFERENTIATE STEM CELLS AND TREAT CANCER
WO2019046467A1 (en) 2017-08-29 2019-03-07 Rutgers, The State University Of New Jersey INDAZOLES THERAPEUTIC
WO2019046465A2 (en) * 2017-08-29 2019-03-07 Rutgers, The State University Of New Jersey THERAPEUTIC INDOLES
CN113004286B (zh) * 2019-12-20 2022-08-12 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的三环类化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4705015B2 (ja) 2003-04-03 2011-06-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング カルボニル化合物
DE10315377A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Carbonylverbindungen
US20050080367A1 (en) 2003-06-18 2005-04-14 Phillip March Pressurizing compression apparatus for body part extremities
DE502004001289D1 (de) 2003-06-18 2006-10-05 Merck Patent Gmbh PYRROLIDIN-1,2-DICARBONSÄURE-1-i(4-ETHINYL-PHENYL)-AMIDö-2-i(PHENYL)-AMIDö DERIVATE ALS INHIBITOREN DER KOAGULATIONSFAKTOREN XA UND VIIA ZUR BEHANDLUNG VON THROMBOSEN
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
CA2765527A1 (en) 2009-06-24 2010-12-29 Satoshi Suetsugu N-substituted-cyclic amino derivative
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
WO2014014050A1 (ja) * 2012-07-19 2014-01-23 大日本住友製薬株式会社 １－（シクロアルキルカルボニル）プロリン誘導体

Also Published As

Publication number Publication date
WO2015107724A1 (ja) 2015-07-23
US9718840B2 (en) 2017-08-01
AU2014378428A1 (en) 2016-09-01
EP3095786A4 (en) 2017-10-11
CA2939326A1 (en) 2015-07-23
CN106103453A (zh) 2016-11-09
US20170022218A1 (en) 2017-01-26
JPWO2015107724A1 (ja) 2017-03-23
KR20160107322A (ko) 2016-09-13
EP3095786A1 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
HK1226390A1 (zh) 縮合5-噁唑烷酮衍生物
AU361515S (en) Dishrack
AU362944S (en) Lapboard
GB201412117D0 (en) Soundbar
ZA201704602B (en) Dihydroindolizinone derivative
IL248772A0 (en) A consequence of cyclohexyl pyridine
GB201419650D0 (en) Modified heterocyclase
HK1259107A1 (zh) 氨基唑衍生物
GB2559497B (en) Functional wall-tie
AU5585P (en) Lanutah Mandevilla sanderi
AU5593P (en) Lanmissouri Mandevilla sanderi
AU5594P (en) Lanoregon Mandevilla sanderi
AU5591P (en) Lanmontana Mandevilla sanderi
AU5584P (en) Laniowa Mandevilla sanderi
AU5583P (en) Lanminnesota Mandevilla sanderi
AU5596P (en) Lannevada Mandevilla sanderi
AU5286P (en) FLOMANWHW Mandevilla sanderi
AU5287P (en) FLOMANPIW Mandevilla sanderi
AU5285P (en) FLOMANRER Mandevilla sanderi
AU5289P (en) FLOMANFOP Mandevilla sanderi
AU5288P (en) FLOMANTOG Mandevilla sanderi
ZA201500428B (en) Condenser
GB201420537D0 (en) Ireceipt
AU2014264V (en) FlatGL Templetonia retusa
AU2014265V (en) FlatdampGL Westringia dampieri